Despite a rebound in the industry growth over January and February, UBS expects a contraction of -3.0% for the domestic cycle in the second half of FY17.
The fourth quarter is expected to be particularly challenging. The broker finds few positive catalysts and retains a Neutral rating. Target is $5.94.
Sector: Health Care Equipment & Services.
Target price is $5.94.Current Price is $5.94. Difference: $0.00 – (brackets indicate current price is over target). If VRT meets the UBS target it will return approximately 0% (excluding dividends, fees and charges – negative figures indicate an expected loss).